NeoGenomics (NEO - Free Report) closed at $11.46 in the latest trading session, marking a -1.04% move from the prior day. This change was narrower than the S&P 500's daily loss of 2.06%. Elsewhere, the Dow lost 1.81%, while the tech-heavy Nasdaq lost 2.99%.
Heading into today, shares of the operator of cancer-focused testing laboratories had lost 26.05% over the past month, lagging the Medical sector's loss of 6.47% and the S&P 500's loss of 6.47% in that time.
NEO will be looking to display strength as it nears its next earnings release, which is expected to be February 20, 2019. In that report, analysts expect NEO to post earnings of $0.05 per share. This would mark no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $70.43 million, up 3.89% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.18 per share and revenue of $270.65 million. These totals would mark changes of +38.46% and +4.65%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for NEO. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. NEO is holding a Zacks Rank of #1 (Strong Buy) right now.
Digging into valuation, NEO currently has a Forward P/E ratio of 64.33. For comparison, its industry has an average Forward P/E of 21.94, which means NEO is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NEO in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
NeoGenomics (NEO - Free Report) closed at $11.46 in the latest trading session, marking a -1.04% move from the prior day. This change was narrower than the S&P 500's daily loss of 2.06%. Elsewhere, the Dow lost 1.81%, while the tech-heavy Nasdaq lost 2.99%.
Heading into today, shares of the operator of cancer-focused testing laboratories had lost 26.05% over the past month, lagging the Medical sector's loss of 6.47% and the S&P 500's loss of 6.47% in that time.
NEO will be looking to display strength as it nears its next earnings release, which is expected to be February 20, 2019. In that report, analysts expect NEO to post earnings of $0.05 per share. This would mark no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $70.43 million, up 3.89% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.18 per share and revenue of $270.65 million. These totals would mark changes of +38.46% and +4.65%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for NEO. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. NEO is holding a Zacks Rank of #1 (Strong Buy) right now.
Digging into valuation, NEO currently has a Forward P/E ratio of 64.33. For comparison, its industry has an average Forward P/E of 21.94, which means NEO is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NEO in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on NEO - FREE